Optimizing treatment before surgery for HER2-positive breast cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a neoadjuvant (before surgery) treatment plan for people with early-stage HER2-positive breast cancer. The goal is to see if a personalized approach can improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your breast tumor is larger than 2 cm, or has spread to nearby lymph nodes.
- Your cancer is HER2-positive (a specific protein that promotes growth).
- You have not had chemotherapy, anti-HER2 therapy, or radiation for invasive breast cancer before.
- Your heart function is normal (left ventricular ejection fraction greater than 50%).
- You have adequate bone marrow, liver, and kidney function as shown by blood tests.
- You are able to have a breast MRI and provide blood samples for testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests different combinations of targeted therapy and chemotherapy before surgery for HER2-positive breast cancer. It uses a special PET scan to see how well the treatment is working and to help choose the best treatment plan for each person.
This trial tests a combination of targeted drugs and chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink or eliminate the tumor, making surgery more effective.
This trial tests a combination of two drugs, trastuzumab deruxtecan (SHR-A1811) and pertuzumab, given before surgery to shrink HER2-positive breast cancer. It is for women with stage II or III breast cancer who have not yet had treatment and are in good overall health.
This study tests different treatment plans given before surgery for early breast cancer that is both hormone receptor-positive and HER2-positive. The goal is to see which treatment is more effective and to tailor it to each patient.
This trial tests a combination of three targeted drugs (trastuzumab, pertuzumab, and tucatinib) without chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink tumors effectively while avoiding chemotherapy side effects.
This phase 3 trial compares two pre-surgery treatment plans for people with HER2-positive invasive breast cancer that has spread to nearby lymph nodes. It aims to see which plan works better to shrink the tumor before surgery and improve outcomes.
Hear when a new HER2-positive Early-stage Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.